Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | PANK3 | Q9H999 | 5/20 | 0.46 |
| ▸ | RET | P07949 | 8/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702989 | 0.85 | RET (0.58) | PANK3RETDPP4 | |
| SCHEMBL6702674 | 0.82 | RET (0.50) | PANK3RETDPP4 | |
| SCHEMBL9923372 | 0.76 | AKT1 (0.41) | — | |
| SCHEMBL7078845 | 0.76 | RET (0.57) | PANK3RETCHRM4DPP4 | |
| SCHEMBL16430700 | 0.76 | RET (0.57) | PANK3RET | |
| SCHEMBL16420447 | 0.75 | CNR1 (0.47) | CNR1CNR2DPP4OPRM1 | |
| SCHEMBL21520496 | 0.75 | RET (0.57) | PANK3RET | |
| SCHEMBL2554955 | 0.75 | AKT1 (0.47) | CNR1CNR2 | |
| SCHEMBL361749 | 0.74 | AKT1 (0.40) | — | |
| SCHEMBL16418423 | 0.74 | GRIN2D (0.50) | CNR1CNR2OPRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | CNR1 4566/4885CNR2 4648/4885PANK3 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.